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phy. The criteria used for definition of LVNC is that
described by Chin et al. (2), Ichida et al. (3), Pignatelli et al.
(4), and Towbin and Bowles (5), which is the accepted
criteria by cardiologists. The patients screened were re-
cruited from five centers; all of the patients were evaluated
by cardiac and neurologic analyses. All nuclear family
members were evaluated by cardiac exam and genetic
screening; selected subjects (but the majority) were also
screened neurologically. Regarding subject II:1 of family
065, she is the wife of an affected family member. Her
echocardiogram was read as normal, but the specific mea-
surements were not available. It should be noted that she is
not a “blood relationship” of the affected family members
(except her daughter, whose father was affected). Symptom-
atically (as noted), the affected patients commonly com-
plained of muscle fatigue and cramping as well as exercise
intolerance. Because these patients were, in most cases,
effectively treated for heart failure, these symptoms are
beyond expectations for clinically stable, compensated car-
diomyopathy and suggest a primary skeletal muscle func-
tional abnormality. Cypher knock-out mice do have “clini-
cal myopathy” that is probably more severe than our patients
as a result of the heterozygous nature of our mutations (and
the total loss of function of the knock-out animals). This is
common when comparing mouse knock-out models with
autosomal-dominant human subjects. We have shown this
to be the case here as well as in several other publications in
which we identified causative genes for DCM (-
sarcoglycan, dystrophin, MLP, -actinin2) (5,6), and
LVNC (-dystrophin, G4.5) (3).
The 200 control patients are standardized controls as
used in all genetic studies; none had DCM, LVNC, or
cardiac disease (that is why they are called controls). Based
on their comments regarding the knock-out animals and
these statements regarding the control analyses, it is clear
that Drs. Finsterer and Stöllberger (7) do not understand
human molecular genetics and do not understand the
genetic basis of cardiomyopathy. Their queries regarding
the clinical data also demonstrate that they are clearly not
cardiologists and have no experience or understanding of
these clinical diseases. Furthermore, although we agree with
their suggestion that studies of skeletal muscle in patients
with LVNC should be considered, it should be noted that in
their own publications, they are unable to study the skeletal
muscle of over 50% of cases with LVNC. How they can
suggest that 80% of cases have associated skeletal muscle
disease is unclear because they themselves have failed to
perform these analyses. Regarding the points raised about
other causes of LVNC, we have now shown that LVNC is
a genetically heterogeneous disorder with autosomal-
dominant inheritance resulting from mutations in
-dystrobrevin and Cypher/ZASP (1), as well as being
associated with X-linked inheritance due to mutations in
G4.5 (3). No genetic data are available to demonstrate
mitochondrial inheritance thus far. Clearly, the disorder is
complex, and further study is needed. Why ZASP mutations
cause LVNC in some individuals and DCM in others is not
yet known.
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Severe Ostial Saphenous Vein
Graft Disease Leading to Acute
Coronary Syndromes After Proximal
Aorto-Saphenous Anastomoses With
The Symmetry Bypass Connector Device
I read the article by Cavendish et al. (1) with interest. They
described their experience with 320 applications of the
Symmetry Aortic Connector (St. Jude Medical Inc., St.
Paul, Minnesota) in 121 patients. There were 11 (3%)
described failures (proximal occlusion or ostial stenoses).
They do not, however, describe the sizes used (gray, green,
blue, purple), the quality of the conduit, or the quality/size
of the distal target in any of the cases. Furthermore, they do
not describe the anticoagulation protocol they followed after
using this device.
My colleagues and I also have extensive experience with
this device. We recognized early in our experience that
because this product is composed of nitinol, it should be
regarded as an intra-coronary stent. To that end, we
routinely anticoagulate on postoperative day 1 with clopi-
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dogrel (300 mg) followed by a daily dose of 75 mg for a
minimum of 6 weeks (2). We further justify this anticoag-
ulation regimen by the relative state of hypercoagulation we
have previously described, which follows off-pump coronary
artery bypass surgery (3). Because of variation on conduit
size as well as distal runoff, we no longer routinely use the
gray (4.5 to 5.0 mm) or green (5.0 to 5.5 mm) connectors
but limit our practice to the blue (5.5 to 6.0 mm) and purple
(6.0 to 7.0 mm) devices.
The authors do note that the published incidence of
saphenous vein graft failure using conventional suture tech-
nique at one year is 15%. Their reported incidence of graft
occlusion with this Food and Drug Administration-
approved product is one-fifth of this value. It is also
interesting to note that in those patients with early graft
occlusion, the phenomenon occurred in all grafts. This
observation may simply represent poor quality conduit, poor
distal runoff, hypercoagulation, or all of the above.
We continue to employ the symmetry device in our
surgical practice using the aforementioned protocol. There
is no doubt that use of the connector avoids the significant
manipulation of the ascending thoracic aorta so often
associated with catastrophic cerebral vascular accidents.
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REPLY
We agree that device size may account for some cases of
anastomotic device failure, although these data became
available only this month (February 2004), showing a
20.8%, 8.5%, 14.7%, and 0.0% failure rate in gray, green,
blue, and purple sizes, respectively, although these were not
statistically different from each other (1). In our report (2),
mostly green or blue devices were used, but after appreci-
ating that some patients were developing anastomotic device
stenosis, only blue and purple were used. The quality of the
veins and distal targets was felt to be adequate. In addition,
all occlusions were at the proximal anastomoses, rendering
poor distal runoff or technical problems with the distal
anastomosis less likely. All patients received aspirin 325 mg
and clopidogrel 75 mg on the day of the surgery. The aspirin
was given indefinitely, and the clopidogrel was continued
for two to three months.
Although the historical incidence of graft failure is higher
than in our report, our study was a clinical and not an
angiographic study. Thus, we did not evaluate the true
incidence, which is likely underestimated. In addition to the
studies pointed out in our study, a recent angiographic
(three month) report shows that 11%, 5%, and 7% of grafts
were either occluded, had 50% stenosis or 50% stenosis,
respectively (19 of 81, or 23% saphenous vein graft [SVG])
(1). Of note, 18.6% of patients had recurrent cardiac
symptoms, including three cardiac deaths. We have also
identified an additional three patients and six SVGs with
variable amounts of anastomotic device stenosis or occlusion
in whom coronary artery bypass graft was performed in
2002, the time period reported in our article. Two patients
were treated with sirolimus-eluting stents (2 SVGs and
native left circumflex obtuse marginal coronary artery, re-
spectively), and the other with medical therapy.
An important clinical consequence of anastomotic device
stenosis is its aggressive nature, which appears diffuse and
severe with involvement of all SVGs. This is in contrast to
in-stent restenosis, which is more variable and only rarely
leads to involvement of all stents. In this regard, patients
with anastomotic device stenosis can present with global
ischemic episodes that lead to myocardial infarction and
death, which is also unusual with coronary in-stent reste-
nosis. With the publication of additional reports describing
anastomotic device stenosis (1,3), we would reemphasize
increased oversight by regulatory agencies and adequately
powered, randomized controlled trials of such devices,
similar to coronary stent trials.
We believe that these devices will ultimately find their
niche in clinical practice, as the imperative to reduce stroke
during coronary artery bypass grafting is obviously critically
important and has been reflected by the rapid acceptance of
such devices by cardiovascular surgeons. However, improve-
ments in the design of such devices seem to be required to
improve outcomes (i.e., anti-proliferative drug coatings,
improved loading and deliverability, and so forth). Pending
further studies showing long-term efficacy, we continue to
advise limiting their use to patients with a clearly increased
risk of stroke during aortic cross-clamping. In patients in
whom the device needs to be placed, the use of the largest
devices, prolonged dual anti-platelet agents, careful follow-
up, communication between cardiothoracic surgeons and
cardiologists when the device is implanted, and ischemia
testing in the first two to six months are warranted. The
treatment of anastomotic device stenosis will continue to
evolve as we learn more about this new iatrogenic disease.
1141JACC Vol. 44, No. 5, 2004 Letters to the Editor
September 1, 2004:1139–45
